In caring for patients with chronic pain, I have tried all kinds of treatments to reduce bothersome symptoms, hoping to achieve improvements that are better than the usual one or two points on a visual analog scale. The list of these treatments is long—no doubt, you have tried the same ones—and include the expected array…
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates
Information on New Approvals and Medication Safety
Colcrys Approval Triggers Questions
Some rheumatologists question the depth of research and the approval’s implications for patient access
Drug Updates
Information on New Approvals and Medication Safety
The Law of Unintended Consequences Rears Its Head
A program to improve drug safety has increased drug prices for patients with gout and FMF
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates: Information on New Approvals and Medication Safety
Information on New Approvals and Medication Safety
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Drug Updates
Information on News Approvals and Medication Safety